Tumor-derived Parathyroid Hormone-Related Protein Is Associated with Suppression of Cytochrome P450 Expression: Evidence From Multimodal Transcriptomics.
Tumor-derived PTHrP may be linked to the suppression of drug-metabolizing enzymes, but further research is needed to clarify its role and clinical implications.
Where it sits
this study against the rest of the abaloparatide (tymlos) corpusSummary and findings
This study investigated the association between tumor-derived parathyroid hormone-related protein (PTHrP) and the suppression of cytochrome P450 (CYP) enzymes in a rat cachexia model. Significant downregulation of CYP3A, CYP1A, CYP2C, CYP2D, and CYP2E1 was observed in both the liver and small intestine. Additionally, a negative correlation between PTHrP and CYP gene expression was found in human hepatocellular carcinoma data sets.
Abstract
Cancer cachexia is frequently associated with altered pharmacokinetics and increased chemotherapy toxicity due to the downregulation of cytochrome P450 (CYP) enzymes. However, the molecular mechanisms driving this broad metabolic suppression remain poorly understood. This study investigated whether tumor-derived parathyroid hormone-related protein (PTHrP) is associated with, and may contribute to, suppression of multiple CYP families. In a rat cachexia model, protein expression of CYP3A, CYP1A, CYP2C, CYP2D, and CYP2E1 was significantly downregulated in both the liver and small intestine. Consistent with these changes, pharmacokinetic analyses using a CYP substrate cocktail demonstrated markedly increased AUC and reduced clearance for probe drugs. In vitro experiments showed that PTHrP treatment reduced these CYP isoforms in primary rat hepatocytes. In human data sets, analysis of The Cancer Genome Atlas (TCGA) hepatocellular carcinoma (HCC) data set revealed a significant negative correlation between PTHrP and CYP gene expression, together with enrichment of NF-κB-related transcriptional programs. Furthermore, multimodal analysis using single-cell RNA sequencing and spatial transcriptomics demonstrated that PTHrP-high tumor regions exhibit suppressed xenobiotic metabolism. Additionally, in breast cancer liver metastases, high tumor PTHrP expression correlated with reduced CYP expression in surrounding nontumor hepatocytes, consistent with a possible paracrine relationship. Collectively, these results support an association between tumor-derived PTHrP and suppression of drug-metabolizing programs. They further suggest that PTHrP may be one contributing factor, but not definitive proof of a principal suppressor, and should therefore be considered a candidate biomarker requiring further mechanistic and clinical validation.
Background
This paper addresses the impact of tumor-derived parathyroid hormone-related protein (PTHrP) on cytochrome P450 (CYP) enzyme expression, which is crucial for drug metabolism. Prior research has indicated that cancer cachexia alters pharmacokinetics and increases chemotherapy toxicity, but the underlying mechanisms remain unclear. Understanding the role of PTHrP could shed light on metabolic suppression in cancer and its implications for treatment.
Methods
The study utilized a rat cachexia model to assess protein expression of CYP enzymes. Pharmacokinetic analyses were performed using a CYP substrate cocktail. In vitro experiments involved primary rat hepatocytes treated with PTHrP. Human data were analyzed from The Cancer Genome Atlas (TCGA) hepatocellular carcinoma data set, employing multimodal analysis techniques.
Results
Significant downregulation of CYP enzymes was observed in both the liver and small intestine of the rat model. Pharmacokinetic analyses indicated increased AUC and reduced clearance for probe drugs, although specific numeric values were not provided. The TCGA analysis revealed a significant negative correlation between PTHrP and CYP gene expression.
Interpretation
The findings suggest an association between PTHrP and CYP suppression, aligning with previous literature on the metabolic effects of cancer. However, the clinical significance of these results remains uncertain, particularly given the reliance on animal models and the need for further validation. The study highlights PTHrP as a potential biomarker but does not establish it as a definitive suppressor of CYP expression.
Key findings
- CYP3A, CYP1A, CYP2C, CYP2D, and CYP2E1 protein expression significantly downregulated in liver and small intestine in rat model.
- Pharmacokinetic analyses showed markedly increased AUC and reduced clearance for probe drugs.
- In human TCGA data set, significant negative correlation between PTHrP and CYP gene expression.
- PTHrP-high tumor regions exhibited suppressed xenobiotic metabolism in multimodal analysis.
- High tumor PTHrP expression correlated with reduced CYP expression in surrounding nontumor hepatocytes.
Limitations
- Relies on a rat model, which may not fully represent human physiology.
- Human data derived from TCGA, which may have confounding factors.
- No specific numeric findings reported for pharmacokinetic analyses.
- Further mechanistic and clinical validation required.